Japanese recommendation moves edoxaban closer to first approval
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo's oral Factor Xa inhibitor edoxaban has received its first approval recommendation worldwide, in Japan as Lixiana for the prevention of venous thromboembolism (VTE) after major orthopaedic surgery.